BioNxt为MS制作的新型光纤薄膜显示,生物利用率提高40%,朝着人类试验的方向发展。 BioNxt's new cladribine thin film for MS shows 40% higher bioavailability, advancing toward human trials.

生物Nxt解决方案公司通过其用于多发性硬化症的口服薄膜 (ODF) 配方的克拉迪宾实现了超过40%的高生物利用率,使该计划向首次在人体临床试验迈进. BioNxt Solutions Inc. has achieved over 40% higher bioavailability with its sublingual oral thin film (ODF) formulation of cladribine for multiple sclerosis, advancing the program toward first-in-human clinical trials. 该公司专注于临床规划、制造和监管协调,利用Cladribine的既定安全配置来简化发展。 The company is focusing on clinical planning, manufacturing, and regulatory alignment, leveraging cladribine’s established safety profile to streamline development. 为改善病人的就诊率而设计的ODF平台正在扩大,以治疗脊髓灰质炎,估计全球有140万人受到影响。 The ODF platform, designed to improve patient adherence, is being expanded to treat myasthenia gravis, a condition affecting an estimated 1.4 million people globally. 由于MS市场价值超过10亿美元,而MG市场预计到2032年将达到67亿美元,BioNxt公司的目标是追求资本高效的商业化和伙伴关系之路。 With the MS market valued at over $1 billion and the MG market projected to reach $6.7 billion by 2032, BioNxt aims to pursue a capital-efficient path to commercialization and partnerships.